- Xtandi patient on Medicare — with supplement — pays $441.97 per month
- 2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology
- WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDS
- Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&D
- China: as PCT patent filings increase, GDP growth has decreased
- Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countries
- KEI comment on USTR's 2016 Special 301 report
- Transparency of patents on medicines and other technologies
- WHO releases program of work and progress report in advance of Consultative Expert Working Group on R&D (2-4 May 2016)
- 2015 Oct 16 version: RCEP draft text for investment chapter
KEI has the floor.
>> KEI: Thank you Mr. Chairman. KEI would be as concerned as anyone of piracy, of content that's provided over cable systems. I think, however, it will be interesting for the association of broadcasters, the APP, if they could explain if in any of the countries where they have problems with people stealing cable signals if it's actually not already against the law to do that.
SCCR 31: Day 3 on Broadcasting. How far does the EU want to go with rights to broadcasting &cablecasting?Submitted by Manon Ress on 9. December 2015 - 3:55
(4) The provisions of this Treaty shall apply mutatis mutandis to the protection of
cablecasting organizations in respect of their cablecasts.
The North American broadcasters represented by Erica Edler
>> Thank you, Mr. Chairman. Nava represents broadcasters in North America, Canada, the United States and Mexico. I would like to thank the Chairman for his consolidated text which has served to focus discussions on some of the key issues on a new treaty for broadcasters.
>> Good afternoon. I'm speaking on behalf of electronic information for libraries, the works with libraries in developing and transitioning countries. I'd like to make a comment on the object of protection that has been under discussion here this afternoon. And the importance that any new instrument that might be created limits the object of protection to the signal and not to any underlying content.
Martin Moscoso, the Chair, invited NGOs' comments.
>> KEI: Thank you, Mr. Chairman. In listening to the conversation today and yesterday on this notion of signal versus the content, or container versus the content, it sounds appealing and people have been talking about this now for some years, the idea that you can separate the idea that there is a signal and there is content and things like that.
4pm Day 2 Paragraph 3 of Object of protection
(3) Broadcasting organizations shall also enjoy protection for simultaneous or near simultaneous retransmission by any means as if such transmission were a broadcast.
Day 2 SCCR31 Object of Protection discussion started a 12:45pm. At 1pm we left for lunch and a meeting on education.
II. OBJECT OF PROTECTION
(1) The protection granted under this Treaty extends only to broadcasts transmitted by, or
on behalf of, a broadcasting organization, but not to works or other protected subject
matter carried on them.
(2) The provisions of this Treaty shall not provide any protection in respect of mere
retransmissions by any means.
(3) Broadcasting organizations shall also enjoy protection for simultaneous or near
Day 2 of SCCR31. The morning session was well attended and took place in the "old" and smaller meeting room. Delegates and NGOs can see each other in this room and it was leading to quite a bit of diplomacy and thus most probably consensus. Here is a selection of interventions regarding definitions of retransmission as stated in the Chair's text under discussion:
(d) (1) “retransmission” means the transmission by any means of a broadcast [/cablecast] by any other entity than the original broadcasting [/cablecasting] organization, whether
WIPO SCCR 31 is having a text based discussion of the language for a proposed broadcasting treaty. The meeting is open to NGOs, instant transcripts are streamed over the Internet, and the proceedings are webcast. I was allowed to make to technical interventions this afternoon on the definitions. This is a slightly edited version of my second intervention, on the question of whether or not to have separate definitions for broadcasting and cable casting.
The Delegation of India made the following elegant but extremely to the point statement:
Opening Statement by India on the Broadcasting Treaty at the 31st session of the Standing Committee Copyright and Related Rights at WIPO on 7 December 2015, delivered by Dr. Sumit Seth, First Secretary (Economic)
Thank your Mr. Chairman
DAY 1 (12/7/15) SCCR 31 Re Definitions
This is the text the member states are dicussing this afternoon:
For the purposes of this Treaty:
(a) “signal” means an electronically generated carrier capable of transmitting a broadcast or
cablecast encrypted or not which carries the programmed output of a broadcasting organization.
(b) (1) “broadcasting” means the transmission by wireless means for reception by the
public of sounds or of images or of images and sounds or of the representations thereof, such
At the close of the last meeting (June 29 to July 3, 2015), the WIPO Standing Committee on Copyright and Related Rights (SCCR) requested that the Chair prepare for its next session (December 7 to 11, 2015) a "consolidated text" with respect to 1) definitions, 2) object of protection, and 3) rights to be granted for the proposed treaty for the protection of broadcasting and cablecasting organizations.
1 December 2015
World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP 23)
KEI Statement on Patents and Health
Thank you Madame Chair
KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
November 23, 2015
Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine for the treatment of the hepatitis C virus (HCV), and offers comments on the agreement.